Transforming the Treatment of Heart Failure
The Corvia® Atrial Shunt is a novel heart failure (HF) therapy specifically designed to reduce the symptoms associated with high pressures in the heart and lungs. It is the world’s first atrial shunt intended to reduce heart failure hospitalizations and improve quality of life.
Healthcare Professionals
Learn about the Corvia Atrial Shunt, including study results, peer-reviewed publications, and patient identification.
Learn about the Corvia Atrial Shunt, including study results, peer-reviewed publications, and patient identification.
Heart Failure
Learn about the different types of heart failure, the symptoms, and the treatment options.
Learn about the different types of heart failure, the symptoms, and the treatment options.
Clinical Evidence
Review the clinical evidence for the Corvia Atrial Shunt.
Review the clinical evidence for the Corvia Atrial Shunt.
550+ Patients
have received the Corvia Atrial Shunt
100+ Hospitals
with Corvia Atrial Shunt experience
17 Countries
in which the Corvia Atrial Shunt has been implanted
7+ Years
post-implant for the first Corvia Atrial Shunt patients
RESPONDER-HF Clinical Study
A clinical trial to confirm the efficacy of the Corvia Atrial Shunt in heart failure patients with EF ≥40%
Breakthrough Device Designation
The Corvia Atrial Shunt receives a breakthrough device designation from the FDA.
Publications
The Corvia Atrial Shunt is the most clinically studied atrial shunt for the reduction of Left Atrial Pressure (LAP) in HFpEF/HFmrEF patients.